AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

Anti-SynDig1 Monoclonal Antibody

Technology Benefits: L42/17 is the first anti-SynDig1 protein monoclonal antibody

Technology Application: Recognize endogenous target protein, SynDig1, in tissue Recognize recombinant SynDig1 protein

Detailed Technology Description: Researchers at the University of California, Davis have developed anti-SynDig1 protein monoclonal antibody L42/17. The hybridoma is available for bailment as tangible research property. Antibodies are available for sale from the UC Davis/NIH Neuromab Facility. Additional information, including data sheets, can be found by searching the Neuromab Catalog.

Others: Related Materials
Kalashnikova, E., Lorca, R., Kaur, I., Barisone, G., Li, B., Ishimaru, T., Trimmer, J., Mohapatra, D., and Díaz, E., 2010, SynDIG1: An Activity-Regulated, AMPA- Receptor-Interacting Transmembrane Protein that Regulates Excitatory Synapse Development, Neuron, v. 65, p. 80-93.
UC Davis researchers identify brain protein for synapse development

Tech ID/UC Case
20745/2010-376-0

Related Cases
2010-376-0

*Abstract: Monoclonal antibody against SynDig.

*Principal Investigator: Name: Elva Diaz
Department:

Name: James Trimmer
Department:

Country/Region: USA

For more information, please click Here